Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

ASH 2019 | Ruxolitinib in the real world: myelofibrosis

Aaron Gerds • 10 Dec 2019
ASH 2019
Myelofibrosis Myeloproliferative Neoplasms Ruxolitinib

Aaron Gerds, MD, MS, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, discusses the real-world analysis of ruxolitinib treatment patterns and outcomes among patients with myelofibrosis (MF). Dr Gerds highlights how there continues to be a need for additional therapeutic options for MF. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.

More from Aaron Gerds

Using artificial intelligence to accelerate patient eligibility screening in clinical trials 1:52
Using artificial intelligence to accelerate patient eligibility screening in clinical trials
Aaron Gerds • 5 Dec 2025
Hematocrit control among patients with high- or low-risk PV receiving SoC treatment in the US 2:03
Hematocrit control among patients with high- or low-risk PV receiving SoC treatment in the US
Aaron Gerds • 5 Dec 2025
Practical advice for community physicians managing patients with anemia and myelofibrosis 1:18
Practical advice for community physicians managing patients with anemia and myelofibrosis
Aaron Gerds • 23 Aug 2025
Mechanisms driving anemia in myelofibrosis and approaches under development for this complication 2:11
Mechanisms driving anemia in myelofibrosis and approaches under development for this complication
Aaron Gerds • 23 Aug 2025

Related Videos

Patient-reported outcomes in the Phase III VERIFY trial of rusfertide for polycythemia vera 2:04
Patient-reported outcomes in the Phase III VERIFY trial of rusfertide for polycythemia vera
Aniket Bankar • 8 Dec 2025
12-month primary endpoint analysis from the Phase III ROP-ET study of ropeginterferon alfa-2b in ET 2:25
12-month primary endpoint analysis from the Phase III ROP-ET study of ropeginterferon alfa-2b in ET
Jean-Jacques Kiladjian • 8 Dec 2025
Genome editing for treatment of JAK2 V617F-driven myeloproliferative neoplasms 1:39
Genome editing for treatment of JAK2 V617F-driven myeloproliferative neoplasms
Roman Doll • 7 Dec 2025
Using artificial intelligence to accelerate patient eligibility screening in clinical trials 1:52
Using artificial intelligence to accelerate patient eligibility screening in clinical trials
Aaron Gerds • 5 Dec 2025
The content of VJHemOnc is intended for healthcare professionals